PE20141115A1 - Comprimido de desintegracion oral - Google Patents

Comprimido de desintegracion oral

Info

Publication number
PE20141115A1
PE20141115A1 PE2013001471A PE2013001471A PE20141115A1 PE 20141115 A1 PE20141115 A1 PE 20141115A1 PE 2013001471 A PE2013001471 A PE 2013001471A PE 2013001471 A PE2013001471 A PE 2013001471A PE 20141115 A1 PE20141115 A1 PE 20141115A1
Authority
PE
Peru
Prior art keywords
active ingredient
fine granules
pharmaceutically active
copolymer
methyl methacrylate
Prior art date
Application number
PE2013001471A
Other languages
English (en)
Inventor
Shiro Ishii
Yutaka Ebisawa
Takayuki Okabe
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45509604&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20141115(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE20141115A1 publication Critical patent/PE20141115A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

REFERIDO A UN COMPRIMIDO DE DESINTEGRACION ORAL QUE COMPRENDE: i) GRANULOS FINOS QUE MUESTRAN UNA LIBERACION CONTROLADA DE UN INGREDIENTE FARMACEUTICAMENTE ACTIVO, QUE COMPRENDE GRANULOS FINOS QUE CONTIENEN UN INGREDIENTE FARMACEUTICAMENTE ACTIVO Y UNA CAPA DE RECUBRIMIENTO QUE COMPRENDE COPOLIMERO DE ACIDO METACRILICO/ACRILATO DE METILO/METACRILATO DE METILO, LOS GRANULOS FINOS ESTAN RECUBIERTOS CON MAS DEL 80% Y NO MAS DEL 300% EN PESO DEL COPOLIMERO Y ii) GRANULOS FINOS QUE MUESTRAN UNA LIBERACION CONTROLADA DE UN INGREDIENTE FARMACEUTICAMENTE ACTIVO, QUE COMPRENDE EL INGREDIENTE FARMACEUTICAMENTE ACTIVO Y UNA CAPA DE RECUBRIMIENTO QUE COMPRENDE: a) UN COPOLIMERO DE ACRILATO DE ETILO/METACRILATO DE METILO Y b) UNO O VARIOS TIPOS DE POLIMEROS TAL COMO FTALATO DE HIPROMELOSA, ACETATO SUCCINATO DE HIDROXIPROPILMETILCELULOSA, ENTRE OTROS. EL INGREDIENTE FARMACEUTICAMENTE ACTIVO ES LANZOPRAZOL, UNA DE SUS FORMAS OPTICAMENTE ACTIVOS O SUS SALES. DICHAS CAPAS DE RECUBRIMIENTO COMPRENDEN UN PLASTIFICANTE. ADEMAS EL COMPRIMIDO COMPRENDE UN ADITIVO TAL COMO ALCOHOL DE AZUCAR HIDROSOLUBLE
PE2013001471A 2010-12-27 2011-12-26 Comprimido de desintegracion oral PE20141115A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201061427384P 2010-12-27 2010-12-27

Publications (1)

Publication Number Publication Date
PE20141115A1 true PE20141115A1 (es) 2014-09-12

Family

ID=45509604

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013001471A PE20141115A1 (es) 2010-12-27 2011-12-26 Comprimido de desintegracion oral

Country Status (23)

Country Link
US (1) US20130273157A1 (es)
EP (1) EP2658530A2 (es)
JP (1) JP2014501224A (es)
KR (1) KR20140007364A (es)
CN (1) CN103402500A (es)
AR (1) AR084610A1 (es)
AU (1) AU2011350396A1 (es)
BR (1) BR112013014875A2 (es)
CA (1) CA2823166C (es)
CL (1) CL2013001793A1 (es)
CO (1) CO6731132A2 (es)
CR (1) CR20130327A (es)
EA (1) EA028217B1 (es)
EC (1) ECSP13012718A (es)
MA (1) MA34768B1 (es)
MX (1) MX2013007588A (es)
PE (1) PE20141115A1 (es)
SG (2) SG190905A1 (es)
TN (1) TN2013000220A1 (es)
TW (1) TW201304823A (es)
UY (1) UY33841A (es)
WO (1) WO2012091153A2 (es)
ZA (1) ZA201304617B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2254556A2 (en) 2008-03-11 2010-12-01 Takeda Pharmaceutical Company Limited Orally-disintegrating solid preparation
EP2797597B1 (en) 2011-12-28 2020-02-26 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
PE20142454A1 (es) 2011-12-28 2015-02-07 Global Blood Therapeutics Inc Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido
GB201303781D0 (en) 2013-03-04 2013-04-17 Gauthier Pierre Pascal Oral timer device and method of using same
CN111454200A (zh) 2013-03-15 2020-07-28 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
SG11201507453VA (en) 2013-03-15 2015-10-29 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
CA2903220C (en) 2013-03-15 2023-01-24 Qing Xu Aldehyde compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
SG10201911668VA (en) 2014-02-07 2020-01-30 Global Blood Therapeutics Inc Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
EP3218349A2 (en) 2014-11-14 2017-09-20 Gemphire Therapeutics Inc. Processes and intermediates for preparing , -dicarboxylic acid-terminated dialkane ethers
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
SG10201912511WA (en) 2015-12-04 2020-02-27 Global Blood Therapeutics Inc Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
TWI825524B (zh) 2016-05-12 2023-12-11 美商全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
TW202332423A (zh) * 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
AR111786A1 (es) * 2017-05-11 2019-08-21 Gemphire Therapeutics Inc Composiciones de gemcabeno y su uso
CA3069563A1 (en) 2017-07-10 2019-01-17 Takeda Pharmaceutical Company Limited Preparation comprising vonoprazan
CN108576205B (zh) * 2018-03-22 2022-01-04 湖北省农业科学院农产品加工与核农技术研究所 一种草莓联合干燥的处理方法
US11014884B2 (en) 2018-10-01 2021-05-25 Global Blood Therapeutics, Inc. Modulators of hemoglobin

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
JPH072761B2 (ja) 1985-03-20 1995-01-18 不二パウダル株式会社 微結晶セルロ−ス球形顆粒及びその製造法
JPS62277322A (ja) 1986-02-13 1987-12-02 Takeda Chem Ind Ltd 安定化された腸溶性抗潰瘍固形組成物
FR2679451B1 (fr) 1991-07-22 1994-09-09 Prographarm Laboratoires Comprime multiparticulaire a delitement rapide.
DE69331839T2 (de) 1992-01-29 2002-12-12 Takeda Chemical Industries, Ltd. Schnellösliche Tablette und ihre Herstellung
JP2919771B2 (ja) 1995-04-17 1999-07-19 佐藤製薬株式会社 速溶解性錠剤の製造方法及び該製造方法により製造した速溶解性錠剤
JPH0948726A (ja) 1995-08-07 1997-02-18 Tanabe Seiyaku Co Ltd 口腔内速崩壊性製剤およびその製法
JP3828648B2 (ja) 1996-11-14 2006-10-04 武田薬品工業株式会社 ２−（２−ピリジルメチルスルフィニル）ベンズイミダゾール系化合物の結晶およびその製造法
TW385306B (en) 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
EP1121103B1 (en) 1998-05-18 2006-12-20 Takeda Pharmaceutical Company Limited Orally disintegrable tablets comprising a benzimidazole
AR019935A1 (es) 1998-07-28 2002-03-27 Takeda Pharmaceutical Preparacion solida de desintegracion rapida, uso de una hidroxipropil celulosa poco sustituida en dicha preparacion y metodo para mejorar la capacidad dedesintegracion rapida de la misma
TWI289557B (en) 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
WO2001083473A1 (fr) 2000-04-28 2001-11-08 Takeda Chemical Industries, Ltd. Procede de production d'un derive de sulfoxide optiquement actif
US7169799B2 (en) 2000-05-15 2007-01-30 Takeda Pharmaceutical Company Limited Process for producing crystal
ES2367419T3 (es) 2000-12-01 2011-11-03 Takeda Pharmaceutical Company Limited Métodos de producción de cristales.
JP4493970B2 (ja) 2002-10-16 2010-06-30 武田薬品工業株式会社 持続性製剤
CN1964704A (zh) * 2004-03-03 2007-05-16 特瓦制药工业有限公司 包含酸不稳定药物的稳定药用组合物
CN101340897A (zh) * 2005-12-20 2009-01-07 特瓦制药工业有限公司 兰索拉唑口腔崩解片剂
US20070141151A1 (en) * 2005-12-20 2007-06-21 Silver David I Lansoprazole orally disintegrating tablets
EP1837016A3 (en) * 2006-03-08 2008-01-02 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical multiple-unit composition
EP2098250B1 (en) * 2006-12-28 2016-09-28 Takeda Pharmaceutical Company Limited Orally disintegrating solid preparation
EP2254556A2 (en) * 2008-03-11 2010-12-01 Takeda Pharmaceutical Company Limited Orally-disintegrating solid preparation
WO2010008569A1 (en) * 2008-07-17 2010-01-21 Barr Laboratories, Inc. Orally disintegrating solid pharmaceutical dosage forms comprising delayed-release lansoprazole and methods of making and using the same

Also Published As

Publication number Publication date
TW201304823A (zh) 2013-02-01
MX2013007588A (es) 2013-08-09
UY33841A (es) 2012-07-31
EA201390981A1 (ru) 2014-07-30
JP2014501224A (ja) 2014-01-20
CL2013001793A1 (es) 2013-12-06
CN103402500A (zh) 2013-11-20
WO2012091153A2 (en) 2012-07-05
ZA201304617B (en) 2014-08-27
EA028217B1 (ru) 2017-10-31
EP2658530A2 (en) 2013-11-06
ECSP13012718A (es) 2013-12-31
US20130273157A1 (en) 2013-10-17
CO6731132A2 (es) 2013-08-15
BR112013014875A2 (pt) 2016-10-18
CA2823166C (en) 2019-04-09
AU2011350396A1 (en) 2013-07-11
AR084610A1 (es) 2013-05-29
MA34768B1 (fr) 2013-12-03
CR20130327A (es) 2013-08-22
CA2823166A1 (en) 2012-07-05
SG190905A1 (en) 2013-07-31
KR20140007364A (ko) 2014-01-17
WO2012091153A3 (en) 2012-09-07
SG10201602311XA (en) 2016-04-28
TN2013000220A1 (en) 2014-11-10

Similar Documents

Publication Publication Date Title
PE20141115A1 (es) Comprimido de desintegracion oral
UA103844C2 (ru) Фармацевтический состав, который содержит в матрице, которая подвергается эрозии, один или более эфиров фумаровой кислоты
UY33201A (es) Compuestos de pirazol como antagonistas de crth2.
AR122580A2 (es) Forma de dosificación de doxilamina y piridoxina y/o sus metabolitos o sales
EA201400172A1 (ru) Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
CL2013003331A1 (es) Tableta de liberacion inmediata a prueba de alteracion que comprende (i) una matriz, y (ii) una pluralidad de material particulado, que comprende un opiaceo y un polimero de oxido de polietileno de mas de 20.000 g/mol, donde el multiparticulado forma una fase discontinua dentro de la matriz.
AR094548A1 (es) Dispersión sólida físicamente estable
DOP2013000142A (es) Derivados de biciclo[3,2,1]octilamida y sus usos.
TR201010683A1 (tr) Vildagliptin formülasyonları.
EA201400737A1 (ru) Система доставки на основе множества пеллет с немедленным высвобождением активного вещества
RS53363B (en) ORAL PHARMACEUTICAL TABLETS FOR THE CONTROLLED MESALAZINE RELEASE AND THE PROCESS OF OBTAINING THEM
MX2017006858A (es) Composición farmacéutica o nutracéutica con resistencia a la influencia del etanol.
CY1119542T1 (el) Προϊον μικρονισμου που περιλαμβανει οξεικη ουλιπρισταλη
CL2017001186A1 (es) Comprimido multicapa que contiene un fármaco inestable a la luz
CR20150266A (es) Formulaciones de liberación modificada para oprozomib
CO6382109A2 (es) Formulación de depósito de octreotida con niveles de exposición constantemente altos
PH12014502609B1 (en) Multilayer coating form of orally administered pharmaceutical composition containing omega-3 fatty acid or alkyl ester thereof and statin based drug
CL2017002498A1 (es) Piridopirimidinonas y su uso como modulares del receptor nmda
MX2015010449A (es) Composicion farmaceutica multiparticulada que comprende una multitud de dos clases de granulos.
AR071706A1 (es) Una formulacion farmaceutica de cilostazol solida de liberacion sostenida y metodo de preparacion.
BR112015023381A2 (pt) composição de liberação imediata de sovaprevir, composição de sovaprevir de 200 mg, núcleo de comprimido de sovaprevir e comprimido de sovaprevir revestido
PE20131064A1 (es) Preparacion de particulas recubiertas
MX361275B (es) Formulacion de capsula de acido 5-aminosalicilico.
AR081929A1 (es) Formulaciones de levetiracetam de liberacion controlada y metodos para su produccion
JP2013082696A5 (es)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal